Publications
Found 24 results
Filters: Author is F. Liu [Clear All Filters]
“Collinearity analysis of allotetraploid Gossypium tomentosum and Gossypium darwinii”, vol. 15, p. -, 2016.
, “Collinearity analysis of allotetraploid Gossypium tomentosum and Gossypium darwinii”, vol. 15, p. -, 2016.
, “Constructing gene network based on biclusters of expression data”, vol. 15, p. -, 2016.
, “Constructing gene network based on biclusters of expression data”, vol. 15, p. -, 2016.
, , , “Characterization and development of chloroplast microsatellite markers for Gossypium hirsutum, and cross-species amplification in other Gossypium species”, vol. 14, pp. 11924-11932, 2015.
, “Cloning and characterization of 5-enopyruvylshikimate-3-phosphate synthase from Pantoea sp”, vol. 14, pp. 19233-19241, 2015.
, “Construction and characterization of a bacterial artificial chromosome library for the allotetraploid Gossypium tomentosum”, vol. 14, pp. 16975-16980, 2015.
, “DNA repair gene XRCC3 variants are associated with susceptibility to glioma in a Chinese population”, vol. 14, pp. 10569-10575, 2015.
, “Genetic diversity and relationship analysis of Gossypium arboreum accessions”, vol. 14, pp. 14522-14529, 2015.
, “Identification and characterization of the duck enteritis virus (DEV) US2 gene”, vol. 14, pp. 13779-13790, 2015.
, “Inheritance and quantitative trait locus analysis of low-light tolerance in cucumber (Cucumis sativus L.)”, vol. 14, pp. 10609-10618, 2015.
, “Molecular variation of Sporisorium scitamineum in Mainland China revealed by internal transcribed spacers”, vol. 14, pp. 7894-7909, 2015.
, , “Association of a transforming growth factor-β1 polymorphism with acute coronary syndrome in a Chinese Han population”, vol. 13, pp. 6160-6167, 2014.
, “Prevalence and risk factors of overweight and obesity among individuals over 40 years old in Luzhou city”, vol. 13, pp. 9262-9270, 2014.
, “Significant association between lower pulse pressure and increasing levels of a novel type of phospholipid”, vol. 13, pp. 2922-2930, 2014.
, “Identification of a new locus conferring antixenosis to the brown planthopper in rice cultivar Swarnalata (Oryza sativa L.)”, vol. 12, pp. 3201-3211, 2013.
, “Prevalence of diabetes and impaired fasting glucose in Uygur children of Xinjiang, China”, vol. 12, pp. 5007-5012, 2013.
, “Activation of the ERK1/2 pathway by the CaMEK gene via adeno-associated virus serotype 9 in cardiomyocytes”, vol. 11, pp. 4672-4681, 2012.
, Aliaga JC, Deschenes C, Beaulieu JF, Calvo EL, et al. (1999). Requirement of the MAP kinase cascade for cell cycle progression and differentiation of human intestinal cells. Am. J. Physiol. 277: G631-G641.
PMid:10484389
Bueno OF and Molkentin JD (2002). Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ. Res. 91: 776-781.
http://dx.doi.org/10.1161/01.RES.0000038488.38975.1A
PMid:12411391
Cho HS, Chang SH, Chung YS, Shin JY, et al. (2009). Synergistic effect of ERK inhibition on tetrandrine-induced apoptosis in A549 human lung carcinoma cells. J. Vet. Sci. 10: 23-28.
http://dx.doi.org/10.4142/jvs.2009.10.1.23
PMid:19255520 PMCid:2801106
Garrington TP and Johnson GL (1999). Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr. Opin. Cell Biol. 11: 211-218.
http://dx.doi.org/10.1016/S0955-0674(99)80028-3
Hajjar RJ and Samulski RJ (2006). Heart failure: a silver bullet to treat heart failure. Gene Ther. 13: 997.
http://dx.doi.org/10.1038/sj.gt.3302747
PMid:17262904
Hausenloy DJ, Tsang A and Yellon DM (2005). The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc. Med. 15: 69-75.
http://dx.doi.org/10.1016/j.tcm.2005.03.001
PMid:15885573
Kuno Y, Kondo K, Iwata H, Senga T, et al. (1998). Tumor-specific activation of mitogen-activated protein kinase in human colorectal and gastric carcinoma tissues. Jpn. J. Cancer Res. 89: 903-909.
http://dx.doi.org/10.1111/j.1349-7006.1998.tb00647.x
PMid:9818025
Lemieux E, Bergeron S, Durand V, Asselin C, et al. (2009). Constitutively active MEK1 is sufficient to induce epithelial-to-mesenchymal transition in intestinal epithelial cells and to promote tumor invasion and metastasis. Int. J. Cancer 125: 1575-1586.
http://dx.doi.org/10.1002/ijc.24485
PMid:19462441
Li DY, Tao L, Liu H, Christopher TA, et al. (2006). Role of ERK1/2 in the anti-apoptotic and cardioprotective effects of nitric oxide after myocardial ischemia and reperfusion. Apoptosis 11: 923-930.
http://dx.doi.org/10.1007/s10495-006-6305-6
PMid:16547595
Li XM, Ma YT, Yang YN, Liu F, et al. (2009). Downregulation of survival signalling pathways and increased apoptosis in the transition of pressure overload-induced cardiac hypertrophy to heart failure. Clin. Exp. Pharmacol. Physiol. 36: 1054-1061.
http://dx.doi.org/10.1111/j.1440-1681.2009.05243.x
PMid:19566828
Licato LL and Brenner DA (1998). Analysis of signaling protein kinases in human colon or colorectal carcinomas. Dig. Dis. Sci. 43: 1454-1464.
http://dx.doi.org/10.1023/A:1018894227169
PMid:9690379
Lips DJ, Bueno OF, Wilkins BJ, Purcell NH, et al. (2004). MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation 109: 1938-1941.
http://dx.doi.org/10.1161/01.CIR.0000127126.73759.23
PMid:15096454
Manning G, Whyte DB, Martinez R, Hunter T, et al. (2002). The protein kinase complement of the human genome. Science 298: 1912-1934.
http://dx.doi.org/10.1126/science.1075762
PMid:12471243
Mebratu Y and Tesfaigzi Y (2009). How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle 8: 1168-1175.
http://dx.doi.org/10.4161/cc.8.8.8147
PMid:19282669 PMCid:2728430
Pacak CA, Mah CS, Thattaliyath BD, Conlon TJ, et al. (2006). Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ. Res. 99: e3-e9.
http://dx.doi.org/10.1161/01.RES.0000237661.18885.f6
PMid:16873720
Prasad KM, Xu Y, Yang Z, Acton ST, et al. (2011). Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution. Gene Ther. 18: 43-52.
http://dx.doi.org/10.1038/gt.2010.105
PMid:20703310 PMCid:2988989
Simpson P and Savion S (1982). Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Cross-striations, ultrastructure, and chronotropic response to isoproterenol. Circ. Res. 50: 101- 116.
http://dx.doi.org/10.1161/01.RES.50.1.101
PMid:7053872
Treisman R (1996). Regulation of transcription by MAP kinase cascades. Curr. Opin. Cell Biol. 8: 205-215.
http://dx.doi.org/10.1016/S0955-0674(96)80067-6
Voisin L, Julien C, Duhamel S, Gopalbhai K, et al. (2008). Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. BMC Cancer 8: 337.
http://dx.doi.org/10.1186/1471-2407-8-337
PMid:19014680 PMCid:2596176
White JD, Thesier DM, Swain JB, Katz MG, et al. (2011). Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo. Gene Ther. 18: 546-552.
http://dx.doi.org/10.1038/gt.2010.168
PMid:21228882
Yue TL, Wang C, Gu JL, Ma XL, et al. (2000). Inhibition of extracellular signal-regulated kinase enhances Ischemia/ Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ. Res. 86: 692-699.
http://dx.doi.org/10.1161/01.RES.86.6.692
PMid:10747006
“Complete sequence analysis of mitochondrial DNA of aplastic anemia patients”, vol. 11, pp. 2130-2137, 2012.
,
Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, et al. (1999). Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat. Genet. 23: 147.
http://dx.doi.org/10.1038/13779
PMid:10508508
Bohr VA, Stevnsner T and de Souza-Pinto NC (2002). Mitochondrial DNA repair of oxidative damage in mammalian cells. Gene 286: 127-134.
http://dx.doi.org/10.1016/S0378-1119(01)00813-7
Chen D, Cao G, Hastings T, Feng Y, et al. (2002). Age-dependent decline of DNA repair activity for oxidative lesions in rat brain mitochondria. J. Neurochem. 81: 1273-1284.
http://dx.doi.org/10.1046/j.1471-4159.2002.00916.x
PMid:12068075
Chinnery PF and Schon EA (2003). Mitochondria. J. Neurol. Neurosurg. Psychiatr. 74: 1188-1199.
http://dx.doi.org/10.1136/jnnp.74.9.1188
PMid:12933917 PMCid:1738655
Clayton DA (1984). Transcription of the mammalian mitochondrial genome. Annu. Rev. Biochem. 53: 573-594.
http://dx.doi.org/10.1146/annurev.bi.53.070184.003041
PMid:6383200
DiMauro S and Schon EA (2003). Mitochondrial respiratory-chain diseases. N. Engl. J. Med. 348: 2656-2668.
http://dx.doi.org/10.1056/NEJMra022567
PMid:12826641
Gattermann N (2000). From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. Leuk. Res. 24: 141-151.
http://dx.doi.org/10.1016/S0145-2126(99)00160-5
Gattermann N (2004). Mitochondrial DNA mutations in the hematopoietic system. Leukemia 18: 18-22.
http://dx.doi.org/10.1038/sj.leu.2403209
PMid:14614516
Grist SA, Lu XJ and Morley AA (2004). Mitochondrial mutations in acute leukaemia. Leukemia 18: 1313-1316.
http://dx.doi.org/10.1038/sj.leu.2403380
PMid:15129223
Hatfill SJ, La Cock CJ, Laubscher R, Downing TG, et al. (1993). A role for mitochondrial DNA in the pathogenesis of radiation-induced myelodysplasia and secondary leukemia. Leuk. Res. 17: 907-913.
http://dx.doi.org/10.1016/0145-2126(93)90036-K
Lee MS and Levin BC (2002). MitoAnalyzer, a computer program and interactive web site to determine the effects of single nucleotide polymorphisms and mutations in human mitochondrial DNA. Mitochondrion 1: 321-326.
http://dx.doi.org/10.1016/S1567-7249(01)00031-9
Linnartz B, Anglmayer R and Zanssen S (2004). Comprehensive scanning of somatic mitochondrial DNA alterations in acute leukemia developing from myelodysplastic syndromes. Cancer Res. 64: 1966-1971.
http://dx.doi.org/10.1158/0008-5472.CAN-03-2956
PMid:15026331
Penta JS, Johnson FM, Wachsman JT and Copeland WC (2001). Mitochondrial DNA in human malignancy. Mutat. Res. 488: 119-133.
http://dx.doi.org/10.1016/S1383-5742(01)00053-9
Richter C, Park JW and Ames BN (1988). Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc. Natl. Acad. Sci. U. S. A. 85: 6465-6467.
http://dx.doi.org/10.1073/pnas.85.17.6465
PMid:3413108 PMCid:281993
Shadel GS and Clayton DA (1997). Mitochondrial DNA maintenance in vertebrates. Annu. Rev. Biochem. 66: 409-435.
http://dx.doi.org/10.1146/annurev.biochem.66.1.409
PMid:9242913
Shin MG, Kajigaya S, Levin BC and Young NS (2003). Mitochondrial DNA mutations in patients with myelodysplastic syndromes. Blood 101: 3118-3125.
http://dx.doi.org/10.1182/blood-2002-06-1825
PMid:12446454
Suganuma K, Miwa H, Imai N, Shikami M, et al. (2010). Energy metabolism of leukemia cells: glycolysis versus oxidative phosphorylation. Leuk. Lymphoma 51: 2112-2119.
http://dx.doi.org/10.3109/10428194.2010.512966
PMid:20860495
Wulfert M, Kupper AC, Tapprich C, Bottomley SS, et al. (2008). Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp. Hematol. 36: 577-586.
http://dx.doi.org/10.1016/j.exphem.2008.01.004
PMid:18439489
“S323I polymorphism of the C5L2 gene was not identified in a Chinese population with familial combined hyperlipidemia or with type 2 diabetes”, vol. 10, pp. 3256-3266, 2011.
, Aouizerat BE, Allayee H, Cantor RM, Davis RC, et al. (1999). A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11. Am. J. Hum. Genet. 65: 397-412.
http://dx.doi.org/10.1086/302490
PMid:10417282
Cianflone K (2003). Acylation stimulating protein and triacylglycerol synthesis: potential drug targets? Curr. Pharm. Des. 9: 1397-1410.
http://dx.doi.org/10.2174/1381612033454784
PMid:12769731
Cianflone K, Xia Z and Chen LY (2003). Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim. Biophys. Acta 1609: 127-143.
http://dx.doi.org/10.1016/S0005-2736(02)00686-7
Cui W, Lapointe M, Gauvreau D, Kalant D, et al. (2009a). Recombinant C3adesArg/acylation stimulating protein (ASP) is highly bioactive: a critical evaluation of C5L2 binding and 3T3-L1 adipocyte activation. Mol. Immunol. 46: 3207- 3217.
http://dx.doi.org/10.1016/j.molimm.2009.08.013
PMid:19767107
Cui W, Simaan M, Laporte S, Lodge R, et al. (2009b). C5a- and ASP-mediated C5L2 activation, endocytosis and recycling are lost in S323I-C5L2 mutation. Mol. Immunol. 46: 3086-3098.
http://dx.doi.org/10.1016/j.molimm.2009.06.007
PMid:19615750
de Lind van Wijngaarden RF, Cianflone K, Gao Y, Leunissen RW, et al. (2010). Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment. J. Clin. Endocrinol. Metab. 95: 1758-1766.
http://dx.doi.org/10.1210/jc.2009-0656
Faraj M, Sniderman AD and Cianflone K (2004). ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytes. J. Lipid Res. 45: 657-666.
http://dx.doi.org/10.1194/jlr.M300299-JLR200
PMid:14703506
Huertas-Vazquez A, Aguilar-Salinas C, Lusis AJ, Cantor RM, et al. (2005). Familial combined hyperlipidemia in Mexicans: association with upstream transcription factor 1 and linkage on chromosome 16q24.1. Arterioscler. Thromb. Vasc. Biol. 25: 1985-1991.
http://dx.doi.org/10.1161/01.ATV.0000175297.37214.a0
PMid:15976322
Kalant D, MacLaren R, Cui W, Samanta R, et al. (2005). C5L2 is a functional receptor for acylation-stimulating protein. J. Biol. Chem. 280: 23936-23944.
http://dx.doi.org/10.1074/jbc.M406921200
PMid:15833747
MacLaren R, Kalant D and Cianflone K (2007). The ASP receptor C5L2 is regulated by metabolic hormones associated with insulin resistance. Biochem. Cell Biol. 85: 11-21.
http://dx.doi.org/10.1139/o06-207
PMid:17464341
Marcil M, Vu H, Cui W, Dastani Z, et al. (2006). Identification of a novel C5L2 variant (S323I) in a French Canadian family with familial combined hyperlipemia. Arterioscler. Thromb. Vasc. Biol. 26: 1619-1625.
http://dx.doi.org/10.1161/01.ATV.0000222907.72985.0b
PMid:16627811
Maslowska M, Wang HW and Cianflone K (2005). Novel roles for acylation stimulating protein/C3adesArg: a review of recent in vitro and in vivo evidence. Vitam. Horm. 70: 309-332.
http://dx.doi.org/10.1016/S0083-6729(05)70010-8
Paglialunga S, Julien P, Tahiri Y, Cadelis F, et al. (2009). Lipoprotein lipase deficiency is associated with elevated acylation stimulating protein plasma levels. J. Lipid Res. 50: 1109-1119.
http://dx.doi.org/10.1194/jlr.M800430-JLR200
PMid:19237736 PMCid:2681393
Saleh J, Al-Khanbashi M, Al-Maarof M, Al-Lawati M, et al. (2009). Acylation-stimulating protein increases and correlates with increased progesterone levels during the luteal phase of the menstrual cycle. Eur. J. Endocrinol. 160: 301-307.
http://dx.doi.org/10.1530/EJE-08-0784
PMid:19022911
Xiang SQ, Cianflone K, Kalant D and Sniderman AD (1999). Differential binding of triglyceride-rich lipoproteins to lipoprotein lipase. J. Lipid Res. 40: 1655-1663.
PMid:10484612
Xiang X, Ma YT, Fu ZY, Yang YN, et al. (2009). Haplotype analysis of the CYP8A1 gene associated with myocardial infarction. Clin. Appl. Thromb. Hemost. 15: 574-580.
http://dx.doi.org/10.1177/1076029608329581
PMid:19147528
Xie X, Ma YT, Fu ZY, Yang YN, et al. (2009). Association of polymorphisms of PTGS2 and CYP8A1 with myocardial infarction. Clin. Chem. Lab. Med. 47: 347-352.
http://dx.doi.org/10.1515/CCLM.2009.078
PMid:19327107
Xie X, Ma YT, Yang YN, Li XM, et al. (2010a). Alcohol consumption and ankle-to-brachial index: results from the Cardiovascular Risk Survey. PLoS One 5: e15181.
http://dx.doi.org/10.1371/journal.pone.0015181
PMid:21152041 PMCid:2996294
Xie X, Ma YT, Yang YN, Fu ZY, et al. (2010b). Polymorphisms in the SAA1/2 gene are associated with carotid intima media thickness in healthy Han Chinese subjects: the Cardiovascular Risk Survey. PLoS One 5: e13997.
http://dx.doi.org/10.1371/journal.pone.0013997
PMid:21103356 PMCid:2982816
Yang YN, Wang XL, Ma YT, Xie X, et al. (2010). Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. Clin. Appl. Thromb. Hemost. 16: 579-583.
http://dx.doi.org/10.1177/1076029610364522
PMid:20460345
“STAT3 gene polymorphisms and susceptibility to non-small cell lung cancer”, vol. 10, pp. 1856-1865, 2011.
, Abdulghani J, Gu L, Dagvadorj A, Lutz J, et al. (2008). Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol. 172: 1717-1728.
http://dx.doi.org/10.2353/ajpath.2008.071054
PMid:18483213 PMCid:2408430
Barrett JC, Fry B, Maller J and Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
http://dx.doi.org/10.1093/bioinformatics/bth457
PMid:15297300
Barrett JC, Hansoul S, Nicolae DL, Cho JH, et al. (2008). Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat. Genet. 40: 955-962.
http://dx.doi.org/10.1038/ng.175
PMid:18587394 PMCid:2574810
Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, et al. (2009). gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15: 91-102.
http://dx.doi.org/10.1016/j.ccr.2009.01.002
PMid:19185844
Bowman T, Garcia R, Turkson J and Jove R (2000). STATs in oncogenesis. Oncogene 19: 2474-2488.
http://dx.doi.org/10.1038/sj.onc.1203527
PMid:10851046
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, et al. (1999). Stat3 as an oncogene. Cell 98: 295-303.
http://dx.doi.org/10.1016/S0092-8674(00)81959-5
Darnell JE (2005). Validating Stat3 in cancer therapy. Nat. Med. 11: 595-596.
http://dx.doi.org/10.1038/nm0605-595
PMid:15937466
Dauer DJ, Ferraro B, Song L, Yu B, et al. (2005). Stat3 regulates genes common to both wound healing and cancer. Oncogene 24: 3397-3408.
http://dx.doi.org/10.1038/sj.onc.1208469
PMid:15735721
Ferguson LR, Han DY, Fraser AG, Huebner C, et al. (2010). Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn’s disease in a New Zealand population. Mutat. Res. 690: 108-115.
http://dx.doi.org/10.1016/j.mrfmmm.2010.01.017
PMid:20109474
Fletcher S, Drewry JA, Shahani VM, Page BD, et al. (2009). Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem. Cell Biol. 87: 825-833.
http://dx.doi.org/10.1139/O09-044
PMid:19935868
Grivennikov SI and Karin M (2010). Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21: 11-19.
http://dx.doi.org/10.1016/j.cytogfr.2009.11.005
Horinaga M, Okita H, Nakashima J, Kanao K, et al. (2005). Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer. Urology 66: 671-675.
http://dx.doi.org/10.1016/j.urology.2005.03.066
PMid:16140113
Hsieh FC, Cheng G and Lin J (2005). Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem. Biophys. Res. Commun. 335: 292-299.
http://dx.doi.org/10.1016/j.bbrc.2005.07.075
PMid:16081048
Hsu HS, Huang PI, Chang YL, Tzao C, et al. (2011). Cucurbitacin i inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer 117: 2970-2985.
http://dx.doi.org/10.1002/cncr.25869
PMid:21225866
Ito N, Eto M, Nakamura E, Takahashi A, et al. (2007). STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 25: 2785-2791.
http://dx.doi.org/10.1200/JCO.2006.09.8897
PMid:17602083
Jing N, Zhu Q, Yuan P, Li Y, et al. (2006). Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol. Cancer Ther. 5: 279-286.
http://dx.doi.org/10.1158/1535-7163.MCT-05-0302
PMid:16505101
Karin M (2006). Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
http://dx.doi.org/10.1038/nature04870
PMid:16724054
Kreil S, Waghorn K, Ernst T, Chase A, et al. (2010). A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon alpha. Haematologica 95: 148-152.
http://dx.doi.org/10.3324/haematol.2009.011510
PMid:20065083 PMCid:2805737
Lai SY and Johnson FM (2010). Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist. Updat. 13: 67-78.
http://dx.doi.org/10.1016/j.drup.2010.04.001
PMid:20471303
Lin Q, Lai R, Chirieac LR, Li C, et al. (2005). Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am. J. Pathol. 167: 969-980.
http://dx.doi.org/10.1016/S0002-9440(10)61187-X
Parkin DM, Bray F, Ferlay J and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74-108.
http://dx.doi.org/10.3322/canjclin.55.2.74
Sansone P, Storci G, Tavolari S, Guarnieri T, et al. (2007). IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 117: 3988-4002.
http://dx.doi.org/10.1172/JCI32533
PMid:18060036 PMCid:2096439
Scagliotti GV, Longo M and Novello S (2009). Nonsmall cell lung cancer in never smokers. Curr. Opin. Oncol. 21: 99-104.
http://dx.doi.org/10.1097/CCO.0b013e328321049e
PMid:19532009
Shields PG (2002). Molecular epidemiology of smoking and lung cancer. Oncogene 21: 6870-6876.
http://dx.doi.org/10.1038/sj.onc.1205832
PMid:12362269
Siddiquee K, Zhang S, Guida WC, Blaskovich MA, et al. (2007a). Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. U. S. A. 104: 7391-7396.
http://dx.doi.org/10.1073/pnas.0609757104
PMid:17463090 PMCid:1863497
Siddiquee KA, Gunning PT, Glenn M, Katt WP, et al. (2007b). An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem. Biol. 2: 787-798.
http://dx.doi.org/10.1021/cb7001973
PMid:18154266
Stephens M, Smith NJ and Donnelly P (2001). A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68: 978-989.
http://dx.doi.org/10.1086/319501
PMid:11254454
Turkson J (2004). STAT proteins as novel targets for cancer drug discovery. Expert. Opin. Ther. Targets. 8: 409-422.
http://dx.doi.org/10.1517/14728222.8.5.409
PMid:15469392
Vaclavicek A, Bermejo JL, Schmutzler RK, Sutter C, et al. (2007). Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer. Endocr. Relat. Cancer 14: 267-277.
http://dx.doi.org/10.1677/ERC-06-0077
PMid:17639043
Weerasinghe P, Garcia GE, Zhu Q, Yuan P, et al. (2007). Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int. J. Oncol. 31: 129-136.
PMid:17549413
Yang L, Parkin DM, Li LD, Chen YD, et al. (2004). Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br. J. Cancer 90: 2157-2166.
PMid:15150609 PMCid:2409509
Yin W, Cheepala S, Roberts JN, Syson-Chan K, et al. (2006). Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Mol. Cancer 5: 15.
http://dx.doi.org/10.1186/1476-4598-5-15
PMid:16603078 PMCid:1502137
Yin ZJ, Jin FG, Liu TG, Fu EQ, et al. (2010). Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells. J. Surg. Res. Doi: 10.1016/j.jss.2010.03.053.
http://dx.doi.org/10.1016/j.jss.2010.03.053
PMid:20605584
Yu H and Jove R (2004). The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 4: 97-105.
http://dx.doi.org/10.1038/nrc1275
PMid:14964307
Yu H, Pardoll D and Jove R (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9: 798-809.
http://dx.doi.org/10.1038/nrc2734
PMid:19851315